Study summary · research use only
Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6, Leu17] VIP
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this in vitro study using rat exocrine pancreas and a colonic tumor cell line, the authors tested a compound predicted from structure-activity studies of rat growth hormone-releasing factor: [4Cl-D-Phe6, Leu17]VIP. They report it competitively antagonized VIP-stimulated amylase release and VIP-stimulated short-circuit current changes, and inhibited amylase release stimulated by rGRF, high concentrations of secretin, and peptide contaminants of a natural glucagon preparation. The abstract reports it did not inhibit the action of agonists for the secretin, GRF, or glucagon receptors.
Abstract
From structure-activity relationship studies of rat growth hormone-releasing factor (rGFR) on the vasoactive intestinal peptide (VIP) receptor in an in vitro preparation of exocrine pancreas, we predicted that [4Cl-D-Phe6, Leu17]VIP would be a competitive antagonist for the action of VIP. Micromolar concentrations of synthetic [4Cl-D-Phe6, Leu17]VIP competitively antagonized VIP-stimulated amylase release in the pancreatic preparation and VIP-stimulated short-circuit current changes in a colonic tumor cell line. In addition, [4Cl-D-Phe6, Leu17]VIP inhibited amylase release stimulated by rGRF, high concentrations of secretin (agents that act through the VIP receptor), and peptide contaminants in a preparation of natural glucagon. Finally, [4Cl-D-Phe6, Leu17]VIP did not inhibit the action of agonists for the secretin, GRF, or glucagon receptors.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.